91 results
8-K
EX-99.1
XENE
Xenon Pharmaceuticals Inc
29 Feb 24
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:10pm
comprehensive strategy to pursue multiple streams of late-stage clinical development in epilepsy and depression.”
Mr. Mortimer added, “We continue to make
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
products. We will need to develop such abilities if we are to execute on our business strategy to develop and independently commercialize product … effective market access strategy and gain market acceptance for our future products, if any; and
manage our spending as costs and expenses increase due
424B5
XENE
Xenon Pharmaceuticals Inc
29 Nov 23
Prospectus supplement for primary offering
5:05pm
to do so on our behalf, and commercialize therapeutic products. We will need to develop such abilities if we are to execute on our business strategy … and marketing capabilities;
build and implement effective market access strategy and gain market acceptance for our future products, if any
8-K
EX-99.1
rdfyrnedwyj29ai83
7 Nov 22
Other Events
4:06pm
424B5
mwvbey3x7v37xvvxoqt
23 Jun 22
Prospectus supplement for primary offering
4:09pm
424B5
cnom5ges734 jy
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
63s6y40mnu
1 Mar 22
Prospectus supplement for primary offering
5:12pm